


M1069 free base

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-148088A | | |
| CAS No.: | 2459881-03-7 | | |
| Molecular Formula: | C ₂₁ H ₂₆ N ₄ O ₄ S | | |
| Molecular Weight: | 430.52 | | |
| Target: | Adenosine Receptor | | |
| Pathway: | GPCR/G Protein | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

| | | | | | |
|---|---|--------------------------|--------------|------------|------------|
| In Vitro | DMSO : 100 mg/mL (232.28 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | 2.3228 mL | 11.6139 mL | 23.2277 mL |
| | | 5 mM | 0.4646 mL | 2.3228 mL | 4.6455 mL |
| 10 mM | | 0.2323 mL | 1.1614 mL | 2.3228 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | <ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.81 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.81 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.81 mM); Clear solution; Need ultrasonic | | | | |

BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | M1069 (free base) is a selective and orally active, dual A _{2A} /A _{2B} adenosine receptor antagonist with a selectivity of >100 fold against the A ₁ and A ₃ receptors. M1069 (free base) counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity ^{[1][2][3]} . |
|--------------------|--|

REFERENCES

[1]. Rinat Zaynagetdinov, et al. Abstract 3499: M1069 as dual A2A/A2B adenosine receptor antagonist counteracts immune-suppressive mechanisms of adenosine and reduces tumor growth in vivo. *Cancer Res* (2022) 82 (12_Supplement):3499.

[2]. Tanzer Eva-Maria, et al. Preparation of thiazolopyridine derivatives as adenosine receptor antagonists: World Intellectual Property Organization, WO2020152132[P]. 2020-07-30.

[3]. Lillian L Siu, et al. Abstract CT240: A first-in-human study of the dual A2A/A2B adenosine receptor antagonist M1069 in patients with advanced solid tumors. *Cancer Res* (2022) 82 (12_Supplement):CT240.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA